ASCO
Refine Search
Biotechnology
Shares of Replimune closed up nearly 28% at $7.11 on Thursday after the company shared data on its oncolytic virus RP1 (vusolimogene oderparepvec), in combination with Bristol Myers Squibb’s Opdivo (nivolumab), 7 June 2024
Biotechnology
Gilead subsidiary Kite Pharma has announced updated four-year survival data from the ZUMA-3 study of Tecartus (brexucabtagene autoleucel). 5 June 2024
Biotechnology
Treos Bio, a biotech using data science and proprietary biomarkers to develop precision peptide immunotherapies, has presented results from its Phase II OBERTO-301 study. 4 June 2024
Biotechnology
US drugmaker AbbVie is keen not to be left behind in oncology’s antibody-drug conjugate (ADC) race. 4 June 2024
Biotechnology
French pharma major Sanofi released positive new data from the IMROZ Phase III study at the American Society of Clinical Oncology (ASCO) annual meeting. 4 June 2024
Biotechnology
Japanese pharma giant Takeda and Pfizer have announced positive results from the Phase III HD21 trial at the annual meeting of the American Society of Clinical Oncology (ASCO). 3 June 2024
Biotechnology
Faced with plenty of competition from other drugmakers at the 2024 American Society of Clinical Oncology (ASCO) meeting, Novartis has sought to show the strength of its cancer medicines with its latest data. 3 June 2024
Pharmaceutical
USA-based tumor drug resistance specialist Deciphera Pharmaceuticals today announced results from the company’s MOTION pivotal Phase III study of vimseltinib in patients with Tenosynovial Giant Cell Tumor TGCT) in an oral presentation at ASCO. 3 June 2024
Biotechnology
Positive results have been presented from the LAURA Phase III trial on AstraZeneca’s Tagrisso (osimertinib) at the 2024 American Society of Clinical Oncology (ASCO) Annual Meeting. 3 June 2024
Pharmaceutical
Eli Lilly has released updated data from its Phase I/II clinical trial evaluating olomorasib. 3 June 2024
Pharmaceutical
At the 2024 annual meeting of the American Society of Clinical Oncology (ASCO), Bristol Myers Squibb has announced promising results from the Phase III KRYSTAL-12 study. 3 June 2024
Biotechnology
US biotechs Gilead Sciences and Arcus Biosciences on Saturday announced longer-term efficacy and safety results from Arm A1 of the Phase II EDGE-Gastric study. 3 June 2024
Interview
With a steady flow of oncology results emerging from the ongoing ASCO meeting, a company such as Pierre Fabre, which does not have major data to present, might not usually claim the spotlight. 3 June 2024
Biotechnology
Researchers from UK-based biotech Immunocore Holdings shared new data at the American Society of Clinical Oncology (ASCO) meeting on Kimmtrak (tebentafusp-tebn), the first-ever treatment approved for metastatic uveal melanoma (mUM), showing there is treatment benefit for patients with stable disease and any confirmed tumor reduction. 3 June 2024
Pharmaceutical
US cancer-focussed firm Karyopharm Therapeutics presented updated exploratory subgroup analyses from the Phase III SIENDO study in patients with advanced or recurrent TP53 wild-type endometrial cancer at the American Society of Clinical Oncology (ASCO). 2 June 2024
Biotechnology
US healthcare giant Johnson & Johnson (NYSE: JNJ) released new data from the Phase III MARIPOSA study demonstrating the efficacy of first-line treatment with Rybrevant (amivantamab) in combination with lazertinib in non-small cell lung cancer (NSCLC) with epidermal growth factor receptor (EGFR) mutations. 1 June 2024
ASCO 2024
]S pharma giant Pfizer was trading more than 1% higher during Friday morning’s New York activity. 31 May 2024
Biotechnology
With the annual meeting of the American Society of Clinical Oncology (ASCO) now just days away, multiple large drugmakers have lifted the lid on data that they intend to present. 29 May 2024
Biotechnology
The annual meeting of the American Society of Clinical Oncology (ASCO) is set to commence on 2 June in Chicago, with the highly anticipated plenary session taking place on the Sunday. 22 May 2024
Pharmaceutical
Swiss cancer giant Novartis and German drugmaker Bayer are among the latest companies to lift the lid on upcoming data presentations at ASCO 2024. 17 May 2024
Biotechnology
New Jersey, USA-based Merck & Co has announced it will present 140 abstracts at the upcoming annual meeting of the Annual Society of Clinical Oncology (ASCO), including on the anti-PD-1 blockbuster Keytruda (pembrolizumab) and Lynparza (olaparib) - in over 25 types of cancer. 17 May 2019
Pharmaceutical
The world’s biggest pharma company has talked up its data ahead of the world’s biggest pharma conference. 16 May 2019
Biotechnology
After a slow start, there have been better recent sales of Yescarta (axicabtagene ciloleucel), the CAR-T therapy that Gilead Sciences picked up in its $11.9 billion acquisition of Kite Pharma in 2017. 16 May 2019
Pharmaceutical
London-listed AstraZeneca has revealed details of what it will present at the upcoming annual meeting of the American Society of Clinical Oncology (ASCO) at the end of May. 16 May 2019
Pharmaceutical
The American Society of Clinical Oncology (ASCO) and European Society for Medical Oncology (ESMO) have issued a joint statement calling for governments to renew their commitment to fighting cancer. 5 July 2018
Pharmaceutical
Ipsen has been in oncology for a long time — since the 1980s in fact. It's one of the field's top 20 companies. But in a market that’s turbulent, spilling over with established titans and up-and-comers alike, how does the French firm manage to maintain its edge? 15 June 2018
Biotechnology
Data presented on the Folfirinox chemotherapy regimen at the American Society of Clinical Oncology (ASCO) has spelt the end for Targovax’s TG01, a neoantigen cancer vaccine for resected pancreatic cancer. 13 June 2018
Biosimilars
With the annual meeting of the American Society of Clinical Oncology now well behind us, the consensus view is that US pharma giant Merck & Co stole the show with impressive data on its Keytruda in lung cancer. On a negative note, last week saw disappointing clinical trial results from Switzerland’s Roche, resulting in the company giving up on the development of its spinal muscular atrophy drug olesoxime. On the deal-making front, Axovant Sciences’ collaboration with the UK’s Oxford BioMedica for a Parkinson’s disease candidate, that could earn the latter as much as $824 million, attracted attention, and Roche’s deal with Microbiotica has rekindled interest in the microbiome space. Elsewhere, US Food and Drug Administration approval of Fulphila, Mylan’s biosimilar of Amgen’s Neulasta, was a feature. 10 June 2018
Biotechnology
The pressure for companies with cancer assets to come to the party at the American Society of Clinical Oncology (ASCO) Annual Meeting with impressive data presentations is real – and there is a feeling that those that do not steal the show have to present a picture of progress just to keep pace. 5 June 2018
Biotechnology
A combination of Imbruvica (ibrutinib) and Rituxan/MabThera (Rituxan) has shown greater efficacy than the latter drug alone in patients with Waldenström’s macroglobulinemia (WM), a rare and incurable form of non-Hodgkin’s lymphoma (NHL). 5 June 2018
Biotechnology
Presenting at the annual meeting of the American Society of Clinical Oncology (ASCO), France’s Sanofi and USA-based Regeneron Pharmaceuticals have released new positive data for their oncology candidate cemiplimab. 5 June 2018
Biotechnology
Shares in US biotech Nektar Therapeutics were down by as much as 40% after the morning's trading on Monday as markets mulled over news on its development of NKTR-214. 4 June 2018
Biotechnology
There are plenty of immuno-oncology (I-O) drugs in development and Bristol-Myers Squibb’s Opdivo (nivolumab) is the current best-seller of those on the market, but Merck & Co has proven beyond doubt that it undoubtedly has the hottest asset in the space at the present time. 4 June 2018
Pharmaceutical
Data revealed at the 2018 American Society of Clinical Oncology (ASCO) Annual Meeting on Saturday offered a promising signal for AstraZeneca’s antibody drug conjugates (ADC) platform. 4 June 2018
Biosimilars
As the American Society for Clinical Oncology (ASCO) conference got underway on Friday, Samsung Bioepis revealed the results of a one-year follow-up study on SB3, its biosimilar alternative to Roche's blockbuster breast and stomach cancer treatment Herceptin (trastuzumab). 1 June 2018
Pharmaceutical
This week, cancer patients, oncologists and investors alike look ahead to the annual meeting of the American Society of Clinical Oncology (ASCO), which kicks off in Chicago on Friday. 29 May 2018
Biotechnology
Shares of US biotech Loxo Oncology leapt 21% to $167.53 after the firm released an abstract of early-stage data for its RET inhibitor LOXO-292. 18 May 2018
Pharmaceutical
In an Expert View piece, Annie Sullivan, director of corporate social media at Anglo-Swedish pharma major AstraZeneca, discusses the company’s novel approach of being 'a better social media citizen' and how its adoption of this strategy at the ASCO Annual Meeting in 2017 may help evolve the role of pharma on social media. 31 July 2017
Biotechnology
At an unusually quiet annual meeting of the American Society of Clinical Oncology, Joanne Lager and Israel Lowy, the oncology heads of Sanofi (Euronext: SAN) and Regeneron (Nasdaq: REGN), found time to speak with The Pharma Letter to discuss progress in their long-standing collaboration. 12 June 2017
Biotechnology
With so much of the exciting data at ASCO 2017 again surrounding cancer immunotherapies, The Pharma Letter finds confidence that more will follow in the footsteps of Merck & Co's Keytruda (pembrolizumab). 8 June 2017
Sign up to receive email updates
Join industry leaders for a daily roundup of biotech & pharma news
Today's issue
Company Spotlight
A US biotech company dedicated to creating oral drugs with an emphasis on indications in virology and immunology.
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze